Transcribed

SonALAsense: Developing a Safe and Effective Noninvasive Treatment for Cancer.

Oct 5, 2023 · 48m 55s
SonALAsense: Developing a Safe and Effective Noninvasive Treatment for Cancer.
Description

In a new episode of https://www.spreaker.com/user/7078249/tob-itunes-full-show-sonalasense-sdt, Peter Hofland talks with Ely Benaim, MD, the Chief Medical Officer and Executive Vice President Development at SonALAsense and Mark De Souza, Ph.D, President...

show more
In a new episode of The Onco’Zine Brief, Peter Hofland talks with Ely Benaim, MD, the Chief Medical Officer and Executive Vice President Development at SonALAsense and Mark De Souza, Ph.D, President and Chief Executive Officer of SonALAsense.

SonALAsense was founded to create hope in the face of despair with Sonodynamic Therapy (SDT), a non-invasive therapy option using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS) to treat and eradicate deadly cancers like High-Grade Gliomas (HGG) that typically require debilitating brain surgery that often leads to tumor recurrence.

SonALAsense’s SDT uses SONALA-001, a proprietary formulation of aminolevulinic acid (ALA), to disrupt heme metabolism in tumor cells, increasing production of protoporphyrin, a heme precursor. From there, energy from focused ultrasound excites protoporphyrin molecules, which produce reactive oxygen species that destroy cancer cells.

Recently, Hasan Syed, MD, at Children’s National Hospital published a peer-reviewed paper on the first DIPG patient treated with SONALA-001 in the Journal of Neuro-Oncology; a major milestone for this deadly and understudied childhood disease. [1]

Hofland, Benaim and De Souza talk about new technologies in the treatment of difficult to treat cancers.

Reference
[1] Syed HR, Kilburn L, Fonseca A, Nazarian J, Oluigbo C, Myseros JS, Packer RJ, Keating RF. First-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical communication. J Neurooncol. 2023 Apr;162(2):449-451. doi: 10.1007/s11060-023-04269-8. Epub 2023 Apr 12. PMID: 37046110.

About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit our Patreon page, or contact the sales team.

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

The Onco’Zine Brief is made possible, in part, by Java Original Coffee and Roastmasterz by Java Original Coffee.
show less
Information
Author Peter Hofland
Organization Peter Hofland
Website -
Tags

Looks like you don't have any active episode

Browse Spreaker Catalogue to discover great new content

Current

Podcast Cover

Looks like you don't have any episodes in your queue

Browse Spreaker Catalogue to discover great new content

Next Up

Episode Cover Episode Cover

It's so quiet here...

Time to discover new episodes!

Discover
Your Library
Search